Dyne having vHOT as primary endpoint ‘encouraging,’ says H.C. Wainwright

After Dyne Therapeutics (DYN) announced updates for its DYNE-101 program for myotonic dystrophy type 1, which included the company revising the protocol for the registrational expansion cohort of the ACHIEVE trial to switch to video hand opening time as the primary endpoint, H.C. Wainwright believes an increase in the registrational expansion cohort to 60 allows them to have sufficient powering assumptions for vHOT specifically, and “importantly” allows them to detect trends in other secondary endpoints. The analyst, who believes having vHOT as a primary endpoint for an accelerated approval is “encouraging for Dyne’s clinical and commercial strategy,” has a Buy rating and $38 price target on Dyne shares.